RespireRx Pharmaceuticals Inc. (OTCQB:RSPI) Files An 8-K

RespireRx Pharmaceuticals Inc. (OTCQB:RSPI), a leader in the development of medicines for respiratory disorders, including drug-induced respiratory depression and sleep apneas, announced that the Company’s President, CEO and Vice Chairman of the Board of Directors, James S. Manuso, Ph.D., will present at the BIO Investor Forum on Tuesday, October 18, 2016 at 11:00 A.M. Pacific Time. The Forum is sponsored by the Biotechnology Innovation Organization and is scheduled for Tuesday and Wednesday, October 18 and 19, 2016. Dr. Manuso will be available for one-on-one meetings with Forum attendees on both days.

Story continues below

Commented Dr. Manuso, “The presentation at the BIO Investor Forum will allow us to provide investors with an update on RespireRx’s recent reverse stock split, strategic initiatives and progress on research and development programs. In particular, I look forward to discussing our clinical progress in developing novel medicines, including dronabinol, for a variety of respiratory diseases.” Dr. Manuso concluded, “We are pleased to keep our shareholders and other stakeholders informed as to the continuing progress of RespireRx’s scientific, clinical and regulatory initiatives.”

Dr. Manuso’s live presentation and accompanying slides will be accessible on Tuesday, October 18, 2016 at 11:00 A.M. Pacific Time (2:00 P.M. Eastern Time) using the following link:

http://www.veracast.com/webcasts/bio/investorforum2016/69113192151.cfm.

The presentation and slides will be accessible after the presentation by clicking on the same link or on the investors tab on the RespireRx web-site at www.respirerx.com and following the links and instructions. A copy of the slide presentation being presented at the Forum will be submitted in a Form 8-K filing with the U.S. Securities and Exchange Commission prior to the presentation.

About RespireRx Pharmaceuticals Inc.

RespireRx Pharmaceuticals Inc. is a leader in the development of medicines for respiratory disorders, with a focus on drug-induced respiratory depression and sleep apneas. The Company holds exclusive licenses and owns patents and patent applications for certain families of chemical compounds that claim the chemical structures and their uses in the treatment of a variety of disorders, as well as claims for novel uses of known drugs.

RespireRx has a pipeline of medicines in Phase 2 clinical development focused on pharmaceutical treatments for a variety of different breathing disorders. Clinical development in the area of respiratory disorders, particularly drug-induced respiratory depression and sleep apnea, has created opportunities for the development and commercialization of the Company’s compounds.

An ad to help with our costs